Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome

Journal of the American Board of Family Medicine

Volumn 26, Issue 4, 2013, Pages 470-477

  Nakawah, Mohammad Obadah ^a   Hawkins, Clare ^a   Barbandi, Farouk ^a  

^a San Jacinto Methodist Hospital   (United States)

Author keywords

Asthma; Chronic obstructive airway diseases; COPD; Overlap syndrome

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLUCOCORTICOID;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; EDEMA; HUMAN; NEUTROPHIL; OVERLAP SYNDROME; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RESPIRATORY TRACT ALLERGY; REVIEW; SYNDROME; TREATMENT RESPONSE;

ASTHMA; CHRONIC OBSTRUCTIVE AIRWAY DISEASES; COPD; OVERLAP SYNDROME;

ADMINISTRATION, INHALATION; AGED; ASTHMA; BRONCHODILATOR AGENTS; COMORBIDITY; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS;

EID: 84880994463     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2013.04.120256     Document Type: Review

References (50)

1. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease NHLBI/WHO Workshop Report. Updated 2011. Available from: Http://www.goldcopd.org. Accessed February 15, 2013.
3. Douwes J, Gibson P, Pekkanen J, Pearce N. Noneosinophilic asthma: Importance and possible mechanisms. Thorax 2002;57:643-8.
4. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65:384-90.
5. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-30.
6. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-11.
7. Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155:1529-34.
8. O'Byrne PM, Pedersen S, Lamm CJ, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19-24.
9. Sapey E, Stockley RA. COPD exacerbations. 2: Aetiology. Thorax 2006;61:250-8.
10. Hamid Q, Tulic MK. New insights into the pathophysiology of the small airways in asthma. Ann Thorac Med 2007;2:28-33.
11. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
12. Skold CM. Remodeling in asthma and COPD-differences and similarities. Clin Respir J. 2010;4(Suppl 1): 20-7.
13. Vestbo J, Hansen EF. Airway hyperresponsiveness and COPD mortality. Thorax 2001;56(Suppl 2): Ii11-4.
14. Postma DS, Kerstjens HAM. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:S187-92.
15. Scichilone N, Battaglia S, La Sala A, Bellia V. Clinical implications of airway hyper-responsiveness in COPD. Int J Chron Obstruct Pulmon Dis 2006;1: 49-60.
16. Brutsche MH, Downs SH, Schindler C, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax 2006;61:671-7.
17. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: What are its features and how important is it? BMJ 2009;64:728-35.
18. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: Two approximations from the United States and the United Kingdom. Chest 2003;124:474-81.
19. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-24.
20. Panettieri RAJ., Covar R, Grant E, Hillyer EV, Bacharier L. Natural history of asthma: Persistence versus progression-does the beginning predict the end? J Allergy Clin Immunol 2008;121:607-13.
21. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
22. Rasmussen F, Taylor DR, Flannery EM, et al. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: A longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002;165: 1480-8.
23. Orie NGM. The Dutch hypothesis. Chest 2000;117: 299.
24. Fanta CH, Rossing TH, McFadden ER Jr. Glucocorticoids in acute asthma. A critical controlled trial. Am J Med 1983;74:845-51.
25. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7.
26. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence. Ann Intern Med 2001;134:600-20.
27. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(2):CD004403.
28. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010;303:2035-42.
29. Koutsoubari I, Papaevangelou V, Konstantinou GN, et al. Effect of clarithromycin on acute asthma exacerbations in children: An open randomized study. Pediatr Allergy Immunol 2012;23:385-90.
30. Hahn DL, Grasmick M, Hetzel S, Yale S. Azithromycin for bronchial asthma in adults: An effectiveness trial. J Am Board Fam Med 2012;25:442-59.
31. Albert RK, Connett J, Bailey WC, et al. Zithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
32. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
33. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
34. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: Predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71.
35. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003; 290:2301-12.
36. Man SF, McAlister FA, Anthonisen NR, Sin DD. Contemporary management of chronic obstructive pulmonary disease: Clinical applications. JAMA 2003; 290:2313-6.
37. Chhabra SK, Bhatnagar S. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2002;44:91-7.
38. Donohue JF. Therapeutic responses in asthma and COPD-bronchodilators. Chest 2004;126(2 Suppl): 125S-37S; discussion 159S-61S.
39. Shrestha M, O'Brien T, Haddox R, et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to ?-agonist therapy. Ann Emerg Med 1991;20:1206-9.
40. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: A systematic review with meta-analysis. Thorax 2005;60:740-6.
41. Chhabra SK, Pandey KK. Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma. J Asthma 2002;39:375-81.
42. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma: A randomized trial. N Engl J Med 2010;363:1715-26.
43. Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. J Allergy Clin Immunol 2011;128:308-14.
44. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011;128:315-22.
45. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004;(3):CD003269.
46. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: A three-center study. Am J Med 1991;91: 28S-32S.
47. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: A randomized trial. Ann Intern Med 2005;143:317-26.
48. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
49. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994;105:1411-9.
50. Nichols J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy 2007;27:447-54.